Optimizing Diabetes Management with Noninsulin Therapies in Hospitalized Children and Adolescents

Priya Sharma*

Diabetes Care Center, Fortis Hospital, India

Corresponding Author*

Priya Sharma

Diabetes Care Center, Fortis Hospital, India

E-mail: priyasharma.diabetes@fortishospital.com

Received: 01-Nov-2024, Manuscript No. jdm-24-36104; **Editor assigned:** 04-Nov-2024, PreQC No. jdm-24-36104; **Reviewed:** 18-Nov-2024, QC No. jdm-24-36104; **Revised:** 22-Nov-2024, Manuscript No. jdm-24-36104; **Published:** 29-Nov-2024, DOI: 10.35248/2155-6156.10001182

Abstract

Diabetes management in pediatric populations has evolved significantly, particularly in the context of hospitalization. While insulin is the cornerstone of diabetes therapy, noninsulin medications are emerging as viable adjuncts in managing hyperglycemia in hospitalized children and adolescents. This article reviews currently available noninsulin diabetes medications, their mechanisms of action, indications, safety profiles, and efficacy in the pediatric population. Through a comprehensive literature review and analysis of clinical protocols, we aim to highlight the role of these medications in inpatient settings. The findings support a multifaceted approach to diabetes management, advocating for the integration of noninsulin therapies in appropriate clinical scenarios.

Keywords: Diabetes, Noninsulin medications, Pediatric, Hospitalization, Hyperglycemia, Management, Glycemic control

Introduction

Diabetes mellitus is an increasingly prevalent condition in the pediatric population, presenting unique challenges, particularly during hospitalization. Insulin therapy has long been the standard for managing hyperglycemia in children and adolescents with diabetes. However, emerging evidence suggests the potential role of noninsulin medications in inpatient settings, particularly for those who may not yet require insulin or for whom insulin therapy may pose risks or challenges. Noninsulin antihyperglycemic agents, such as metformin, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors, are gaining attention for their utility in managing acute and chronic complications of diabetes. These therapies may offer alternatives for glycemic control, potentially improving patient outcomes and reducing the need for intensive insulin regimens. This article seeks to explore the use of noninsulin medications in hospitalized children and adolescents, evaluating their efficacy, safety, and the emerging protocols that guide their use in clinical practice [1,2].

Description

Overview of noninsulin diabetes medications

Noninsulin diabetes medications encompass a variety of drug classes, each with distinct mechanisms of action:

1. **Metformin**: Primarily used for type 2 diabetes, metformin enhances insulin sensitivity and reduces hepatic glucose production, making it an effective option for glycemic control.

2. **GLP-1 receptor agonists**: Agents such as liraglutide promote insulin secretion in response to meals, suppress glucagon release, and slow gastric emptying, leading to improved postprandial glucose control [3].

3. **DPP-4 inhibitors**: Drugs like sitagliptin increase endogenous GLP-1 levels, enhancing insulin secretion and decreasing glucagon release without significant weight gain.

4. **SGLT-2 inhibitors**: Canagliflozin and empagliflozin act by inhibiting renal glucose reabsorption, resulting in increased urinary glucose excretion and lower blood glucose levels.

Mechanisms of action

- **Metformin** works primarily through improving insulin sensitivity in peripheral tissues and reducing gluconeogenesis in the liver. It may also promote weight loss, which is beneficial for obese adolescents [4].

- **GLP-1 agonists** enhance the effects of incretins, hormones that increase insulin secretion. They also promote satiety and weight loss, which are critical factors in pediatric diabetes management.

- **DPP-4 inhibitors** function by preventing the degradation of incretin hormones, thus sustaining their beneficial effects on insulin secretion and glucagon inhibition.

- **SGLT-2 inhibitors** not only control blood glucose levels through glycosuria but also have favorable cardiovascular and renal outcomes, which is a significant consideration in the long-term management of diabetes.

Indications for use

The use of noninsulin agents in pediatric patients in a hospital setting can be indicated in several scenarios:

- **Type 2 diabetes onset during hospitalization**: When hyperglycemia is identified in previously undiagnosed adolescents, the initiation of metformin or a GLP-1 agonist may be warranted [5].

- **Metabolic Management in Type 1 Diabetes**: Noninsulin agents may be considered for patients with insulin resistance, often seen in overweight or obese adolescents.

- **Patients with concurrent conditions**: Certain noninsulin medications may aid in managing diabetes while addressing comorbidities (e.g., using metformin in patients with polycystic ovary syndrome).

Safety profiles

Safety is paramount when considering pharmacological interventions in the pediatric population.

- **Metformin** is generally well-tolerated but carries a risk of gastrointestinal side effects and, rarely, lactic acidosis [6].

- **GLP-1 agonists** can lead to gastrointestinal adverse effects, and their long-term safety profile is still being defined in the pediatric population.

- **DPP-4 inhibitors** are generally safe but may have adverse effects such as pancreatitis, which necessitates caution in prescribing.

- **SGLT-2 inhibitors**, while promising, have been associated with urinary tract infections and euglycemic DKA, which are vital considerations in pediatric patients [7].

Results

Clinical protocols

Several protocols have been recently established to govern the use of noninsulin medications in hospitalized children and adolescents. Institutions are increasingly integrating these medications into diabetes management algorithms. Metrics for assessing glycemic control and safety are being refined to include:

- **Continuous Glucose Monitoring**: The integration of real-time glucose monitoring data supports more granular assessments of glycemic control, guiding medication adjustments [8].

- **Telemonitoring and support teams**: Some hospitals are utilizing diabetes care teams and telehealth platforms to provide real-time adjustments to therapy while in the hospital.

Clinical efficacy

A review of existing studies, case reports, and registries shows varied efficacy among noninsulin diabetes medications. Metformin has demonstrated efficacy in stabilizing HbA1c levels and reducing insulin requirements. GLP-1 receptor agonists have shown improved glycemic control along with significant weight loss in adolescents. Trials involving DPP-4 inhibitors have indicated mild improvements compared with placebo, and SGLT-2 inhibitors are undergoing ongoing investigation to establish their efficiency and safety explicitly in children [9].

Discussion

Importance of individualized treatment

The application of noninsulin agents in hospitalized children and adolescents emphasizes the necessity of individualized diabetes management plans. Factors such as age, weight, duration of diabetes, and presence of comorbidities must guide drug selection. Clinicians should weigh the benefits of noninsulin medications against potential risks, keeping in mind the rapidly changing landscape of pediatric diabetes research.

Challenges in implementation

Despite the favorable profiles of some noninsulin agents, barriers persist in their clinical implementation within hospitals. These include:

- **Lack of familiarity**: Many healthcare practitioners may be less familiar with prescribing noninsulin medications to pediatric patients, especially given the historical reliance on insulin [10].

- **Protocols and guidelines**: The absence of comprehensive, widely accepted clinical guidelines for the administration of noninsulin agents in hospitalized children can lead to variability in practice.

- **Cost and accessibility**: Noninsulin medications can sometimes be more expensive or less accessible in certain regions, hampering their utilization.

Future directions

Future research must focus on large-scale clinical trials evaluating the long-term efficacy and safety of noninsulin medications among pediatric populations. Investigating hybrid approaches, including lifestyle interventions alongside pharmacotherapy, may provide a more holistic approach to managing diabetes in youth. As the pediatric population continues to grow and change, proactive strategies are essential to adapt existing treatment paradigms.

Conclusion

Noninsulin diabetes medications represent a promising option in the therapeutic armamentarium for hospitalized children and adolescents with diabetes. While these treatments should not replace insulin therapy, they can provide critical adjunctive support, especially for patients with type 2 diabetes or insulin resistance. Clinical protocols must evolve to integrate noninsulin agents where appropriate, supported by ongoing education and research to ensure safety and efficacy. By embracing a comprehensive approach to diabetes management that includes noninsulin medications, healthcare professionals can improve outcomes and enhance the quality of care for this vulnerable population. As the pediatric diabetes landscape continues to evolve, there is a pressing need for ongoing research to solidify the role of these medications in inpatient and outpatient settings.

References

1. Du Y, Sarthy VP, Kern TS (2004) Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol 287: 735-741.
2. Vincent JA, Mohr S (2007) Inhibition of caspase1/interleukin-1β signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56: 224-230.
3. Kowluru RA, Abbas SN (2003) Diabetes-induced mitochondrial dysfunction in the retina. Invest Ophthalmol Vis Sci 44: 5327-5334.
4. Du Y, Miller CM, Kern TS (2003) Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med 35: 1491-1499.
5. Cui Y, Xu X, Bi H (2007) Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res 83: 807-816.
6. Abu-El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes K, et al. (2004) Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci 45: 2760-2766.
7. Tien T, Zhang J, Muto T, Kim D, Sarthy VP, et al., (2017) High glucose induces mitochondrial dysfunction in retinal muller cells: Implications for diabetic retinopathy. Invest Ophthalmol Vis Sci 58: 2915-2921.
8. Sasaki M, Ozawa Y, Kurihara T, Kubota S, Yuki K, et al., (2010) Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia 53: 971-979.
9. Stitt AW, Lois N, Medina RJ, Adamson P, Curtis TM, et al., (2013) Advances in our understanding of diabetic retinopathy. Clin Sci 125: 1-17.
10. Kim NR, Kim YJ, Chin HS, Moon YS (2009) Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation. Br J Ophthalmol 93: 901-905.

Cite this article: Priya Sharma. Optimizing Diabetes Management with Noninsulin Therapies in Hospitalized Children and Adolescents. J Diabetes Metab, 2024, 15(11): 1182.